In women with breast cancer, slow metabolizers of CYP2D6 (carrier state of slow allele CYP2D6*4), endoxifen is formed in the lower levels, and remission period is lower (Figure 4)[6]. This evidence concerns the gene CYP2D6 and breast cancer.